Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responses

HIV Clinical Trials

Volumn 3, Issue 2, 2002, Pages 115-124

  Lori, Franco ^a   Foli, Andrea ^a   Maserati, Renato ^a   Seminari, Elena ^a   Xu, Jianqing ^a   Whitman, Lucia ^a   Ravot, Elisabetta ^a   Alberici, Francesco ^a   Lopalco, Lucia ^a   Lisziewicz, Julianna ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Anti HIV immune response; Hydroxyurea; STI

Indexed keywords

ANTIRETROVIRUS AGENT; CD3 ANTIGEN; CD4 ANTIGEN; DIDANOSINE; GAMMA INTERFERON; HYDROXYUREA; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG WITHDRAWAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; PRIORITY JOURNAL; REBOUND; STATISTICAL ANALYSIS; T LYMPHOCYTE ACTIVATION; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

EID: 0036092039     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/VFRX-6T7X-UQ2W-V0LK     Document Type: Article

References (36)

1. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
2. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
3. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
4. Latent reservoirs of HIV: Obstacles to the eradication of virus
5. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
6. Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment
7. Rebound of HIV-1 viral load after suppression to very low levels
8. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy
9. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment
10. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy
11. Lymphoproliferative response to HIV type 1 p24 in long-term survivors of HIV type 1 infection is predictive of persistent AIDS-free infection
12. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection
13. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load
14. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics
15. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
16. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
17. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes
18. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
19. Hydroxyurea and didanosine long-term treatment prevents HIV break-through and normalizes immune parameters
20. Dynamics of molecular parameters of human immunodeficiency virus type 1 activity in vivo
21. Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir)
22. Hydroxyurea and HIV: 5 years later-from antiviral to immune-modulating effects
23. Control of SIV rebound through structured treatment interruptions during early infection
24. SITT: A Prospective Trial of Strategic Treatment Interruptions
25. An overview of the clinical experience with hydroxyurea
26. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy
27. Both nucleoside and nucleotide analogues are potentiated by hydroxyurea against drug-susceptible and drug-resistant HIV isolates
28. Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: Correlation with disease progression
29. Absence of recoverable infectious virus and unique immune responses in an asymptomatic HIV+ long-term survivor
30. Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection
31. Serological detection of attenuated HIV-1 variants with nef gene deletions
32. Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naive patients with undetectable viraemia
33. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection
34. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection
35. Long-term safety and antiretroviral activity of hydroxyurea and didanosine in HIV-infected patients
36. New antiretroviral drugs in development